Oblique Therapeutics has developed a groundbreaking antibody discovery platform known as AbiProt®. This innovative technology allows for the identification of therapeutic antibodies that bind with high specificity and affinity to target proteins, including those that are traditionally difficult to drug, such as ion channels and G protein-coupled receptors. By utilizing proteases as molecular probes, AbiProt® scans the entire surface of intact proteins to pinpoint accessible antibody binding sites. This capability not only enhances the precision of antibody development but also enables the design of antibodies with specific pharmacological functions, thereby addressing significant unmet medical needs, particularly in pain management.

The company is committed to transforming antibody therapeutics through its advanced scientific approach and collaboration with leading organizations. Recently, Oblique Therapeutics entered into a research agreement with Eli Lilly and Company to leverage the AbiProt® technology for generating antibodies against high-value targets. This partnership aims to accelerate the development of innovative treatments and underscores Oblique's dedication to improving patient outcomes through cutting-edge research and development in the biotechnology sector.

Sweden

Oblique Therapeutics AB (publ.) is a Swedish biotech company developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer. The company uses Abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome.

Oblique Therapeutics

Company Details